24 April 2018
What if you could know that your mild cognitive impairment wouldn't progress in the next decade through the result of two simple neuropsychological tests?
Researchers from the Lisbon School of Medicine, University of Lisbon found that, in some mild cognitive impairment patients, real neuropsychological stability over a decade is possible and that long-term stability could be predicted based on neuropsychological tests measuring memory and non-verbal abstract reasoning.
23 April 2018
Late, but not too late – Screening for olfactory dysfunction as a marker for cognitive impairment in middle-aged
In a large population-based study of randomly selected participants in Germany, researchers found that participants aged 65-74 years with olfactory dysfunction showed impaired cognitive performance. Interestingly, this strong association was not present in younger (55-64 years) or older (75-86 years) participants. Additionally, the effect was more present in women than men.
28 March 2018
Columbia University neurologist William Kreisl, MD, has been studying a smell identification test and explains what it can – and can’t – say about Alzheimer's. His most recent study appears in the Journal of Alzheimer’s Disease. Here, he provides further explanation about his research.
27 March 2018
Detecting diminished dopamine-firing cells inside the brain could reveal earliest signs of Alzheimer’s disease
Sheffield scientists discover a loss of cells that use dopamine may cause part of the brain - responsible for forming new memories - to function less effectively. These findings could revolutionise screening for Alzheimer’s disease, which affects more than 520,000 people in the UK.
22 March 2018
Alzheimer's disease: patients exhibit changes in certain blood lipids that are typical of premature ageing
The neurodegenerative condition known as Alzheimer's disease is the commonest cause of dementia. A research group led by molecular biologists Fabian Dorninger and Johannes Berger at MedUni Vienna's Centre for Brain Research investigated changes in certain lipids (choline phospholipids) in the plasma of elderly people who were healthy and those suffering from Alzheimer's disease.
21 March 2018
The Journal of Alzheimer’s Disease (JAD) celebrates its 20th anniversary during 2018, with the publication of a special anniversary issue (JAD 62:3) in March. This is now available online, with all content open access and freely available to read for all, and features 35 review articles covering 20 years of Alzheimer’s disease (AD) research, plus personal perspectives from researchers in the field.
20 March 2018
New research from the Amen Clinics shows that brain SPECT (single photon emission computed tomography) imaging, a study that measures blood flow and activity patterns, identifies who is likely to get better from depression and who is not. The study is published in the Journal of Alzheimer's Disease, because depression is a highly treatable risk for cognitive decline and Alzheimer's disease.
14 March 2018
Exploring the Role of Cognitive Factors in a New Instrument for Elders' Financial Capacity Assessment
Although the general public and mental health professionals seem to disregard incapacity regarding financial issues and relevant decision making in mild cognitive impairment (MCI), and focus only on severe dementia cases, a PhD study in Greece reveals that noticeable deficits do exist in the handling of financial issues in elders suffering from MCI.
12 March 2018
The ability to generate spoken verbs in infinitive in a given time begins to worsen in the early stages of Alzheimer's disease (AD). Thus, the verb fluency test has been found to be a suitable neuropsychological tool for the detection of healthy aging people at risk of developing cognitive impairment, according to a recent research of the Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain.
7 March 2018
A new study led by Laurent Meijer of ManRos Therapeutics shows that some pyrazole insecticides, of which fipronil is an archetype, trigger enhanced in vitro production of Aβ42/Aβ43 over Aβ40 amyloid peptides in a cell-free, highly purified preparation of γ-secretase, in various cell lines and in neurons differentiated from human-induced pluripotent stem cells (iPSCs) from a healthy or a familial Alzheimer's disease (AD) patient with the APP K724N mutation.